Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company focused on developing anti-cancer therapies for patients with high unmet medical need. The company’s core differentiator is its Drug Response Predictor (DRP®) platform, which is designed to match a drug candidate to the cancer patients most likely to benefit from it based on gene-expression signatures. Allarity has historically built DRP signatures for multiple oncology assets and has in-licensed several drug candidates for DRP-guided development, including stenoparib, LiPlaCis, Irofulven, and dovitinib. The business is still in the development phase, with limited collaboration revenue and no commercial product sales to date. Its value proposition depends on advancing a small number of precision oncology programs through clinical testing and regulatory approval while protecting the underlying DRP intellectual property.

−3 509,7 %

2.13

2.13

— Allarity Therapeutics, Inc.
%
Precision medicine platform10% DRP® signatures and companion diagnostic capabilities used to identify patients most likely to respond to a given anti-cancer therapy.
Clinical-stage oncology drug candidates70% Lead and in-licensed cancer therapeutics being advanced through preclinical and clinical development, especially stenoparib.
Drug development collaborations5% Limited collaboration-based activities and related research support tied to external development programs.
Intellectual property and diagnostics15% Patent filings and proprietary diagnostic assets that protect the DRP platform and future commercialization rights.

Allarity does not yet sell approved drugs commercially, so its near-term counterparties are primarily clinical and...

  • Clinical trial ecosystemprimary

    Investigators, trial sites, CROs, and vendors that support preclinical and clinical development of stenoparib and other oncology assets.

  • Potential pharma and biotech partnersprimary

    Companies that may license, collaborate on, or acquire DRP-guided drug programs to accelerate development and commercialization.

  • Future oncology prescribers and hospitalssecondary

    Oncologists and hospital systems that would use an approved therapy and companion diagnostic to treat selected cancer patients.

  • Patients with high unmet need cancerssecondary

    The intended end beneficiaries of DRP-selected anti-cancer therapies, especially in biomarker-enriched settings.

Allarity is headquartered in the United States and operates as a U.S.-listed clinical-stage biotechnology company...

  • •United States headquarters and reporting base
  • •Australia patent acceptance for the DRP companion diagnostic
  • •International suppliers and third parties used in development work
  • •Potential exposure to tariffs and trade restrictions across borders
  • •No disclosed country-level revenue concentration in the excerpts

Allarity’s strategy is centered on advancing stenoparib and other oncology assets through clinical development using...

01
Clinical advancement of stenoparibshort-term

The lead asset is the main path to future value creation and any commercial revenue.

02
DRP platform validation and protectionmedium-term

The company’s differentiation depends on proving that DRP can improve patient selection and protectable IP can support commercialization.

03
Capital raising and balance sheet supportshort-term

The company needs external funding to sustain development before any product revenue is realized.

The company faces the standard risks of a clinical-stage biotechnology business, including clinical trial failure,...

critical

Clinical development failure

The company’s lead value driver is a drug candidate still requiring preclinical and clinical success before approval.

Scope
stenoparib and other oncology assets
Materiality
high
high

Need for additional capital

The company has limited revenue and funds operations primarily through equity and convertible financing.

Scope
ongoing R&D and corporate overhead
Materiality
high
high

Internal control weakness

Management disclosed a material weakness in internal control over financial reporting, which can lead to misstatements or delayed reporting.

Scope
financial reporting and investor confidence
Materiality
high
high

Regulatory and approval risk

Any future product must satisfy FDA and other regulators, and timelines are uncertain.

Scope
drug approval and commercialization
Materiality
high
medium

Trade and tariff disruption

The company noted uncertainty around tariffs and trade restrictions that could affect partners and suppliers.

Scope
international vendors and third parties
Materiality
medium
Research and development accruals
Can shift expenses between quarters and change reported losses
Prepaid research and advance payments
Creates quarter-to-quarter comparability noise
Stock-based compensation
Affects G&A and total operating expenses
Internal control over financial reporting
Can affect reliability of reported financial statements

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Monopar Therapeutics

MNPR · Pharmaceutical Preparations

Aclaris Therapeutics, Inc.

ACRS · Pharmaceutical Preparations

Acrivon Therapeutics, Inc.

ACRV · Pharmaceutical Preparations

Aprea Therapeutics, Inc.

APRE · Pharmaceutical Preparations

LadRx Corp

Biological Products, (No Diagnostic Substances)

: 11/08/2026